BIOARCTIC AB [CBOE] overview

Eisai will request reconsideration of initial decision for lecanemab in Australia PR Newswire STOCKHOLM, Oct. 16, 2024 STOCKHOLM , Oct. 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab for the treatment of patients with mild...

Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology PR Newswire STOCKHOLM, Aug. 27, 2024 STOCKHOLM , Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical Pharmacology. Exidavnemab is a drug candidate under development aimed at treating diseases such as Parkinson's disease. It is a monoclonal antibody...

Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain PR Newswire STOCKHOLM, Aug. 22, 2024 STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain , for the treatment of mild cognitive impairment (MCI) and mild dementia due to...

Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic PR Newswire STOCKHOLM, Aug. 22, 2024 STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain . BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors. The company will update the market if new information becomes available. The...

Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic PR Newswire STOCKHOLM, Aug. 22, 2024 STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain . BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors. The company will update the market if new information becomes available. The...

Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET PR Newswire STOCKHOLM, Aug. 19, 2024 STOCKHOLM , Aug. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2024 on Thursday, August 29, 2024 , at 08:00 a.m. CET . In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on...

Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET PR Newswire STOCKHOLM, Aug. 19, 2024 STOCKHOLM , Aug. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2024 on Thursday, August 29, 2024 , at 08:00 a.m. CET . In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on...

Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi ® (lecanemab) for the treatment of Alzheimer's disease (AD). Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or...